Medgenics: USD 7 million deal validates Biopump protein platform
One week ahead of BIO-Europe 2009, Medgenics announced its first preclinical development and option agreement with what it described as “a major international biopharmaceutical company that is a market leader in the field of hemophilia.” Read more »